Tennessee Clinical Trials

A listing of Tennessee clinical trials actively recruiting patient volunteers.

Tennessee is a lively and lovely state known as the birthplace of bluegrass and the site of Graceland and Dollywood. It’s also the place to go to see one of America’s most iconic national parks, The Great Smoky Mountain National Park. Nashville is where you can immerse yourself in the history of the music business, while Memphis, Knoxville, and Gatlinburg each offer their own perks and sights. In any of these cities and beyond, sound healthcare is easy to find. Vanderbilt University Medical Center has been ranked #1 in the state, with more than 1,000 acute care beds in service.

Filter by Condition
2026 trials found

Clinical Stabilization of Hypercapnia: NIPPV v HVNI

NCT04709562

This study will evaluate the ability of High Velocity Nasal Insufflation [HVNI] to effect ventilation and related physiologic responses in hypercapnic patients when compared to noninvasive positive pressure ventilation [NIPPV].

Conditions: Hypercapnic Respiratory Failure, Chronic Obstructive Pulmonary Disease, Dyspnea, Hypercapnic Acidosis
Phase: Not Applicable

Characterization of Product Use in Smokers Switching From Cigarettes to a RELX Electronic Nicotine Delivery System

NCT04708106

The study will assess product use behaviors, biomarkers of exposure, subjective effects, and safety in smokers who switch to a RELX ENDS over 8-weeks.

Conditions: Electronic Cigarette Use
Phase: Not Applicable

A Study of PY314 in Subjects With Advanced Solid Tumors

NCT04691375

A Phase 1a/1b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PY314 as a Single Agent and In Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

Conditions: Advanced Solid Tumor

Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Males - A Sub-study of HPTN 083

NCT04692077

This study will establish the minimum safety, tolerability and acceptability data needed to support the use of cabotegravir long-acting injection (CAB LA) in an adolescent population, potentially transforming the field of HIV prevention for young people.

Conditions: HIV Infections

Psychosocial, Behavioral, and Radiologic Changes Following Radiosurgery for Benign Neurologic Disease

NCT04688554

A number of studies from the literature suggest important behavioral, psychosocial, or radiologic changes occur following significant neurologic events or interventions such as stroke, neurosurgery, medications, radiation, systemic therapy, or injury. The purpose of this study is to describe these changes with advanced neurologic imaging and targeted neurologic and neuropsychiatric assessments. This is a non-interventional observational study of minimal risk to participants as there is no medica ...

Conditions: Obsessive-Compulsive Disorder, Pain, Intractable, Depression

A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)

NCT04688164

This is an outpatient, 2-arm, Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of REL-1017 once daily (QD) as an adjunctive treatment of Major Depressive Disorder. Study participants will continue to take their current antidepressant therapy in addition to the study drug or placebo for the duration of the treatment period.

Conditions: Major Depressive Disorder

GEBT Telehealth Administration Usability Study

NCT04684992

The purpose of this study is to establish the usability of a telehealth platform for the administration of GEBT.

Conditions: Gastroparesis
Phase: Not Applicable

Study of Mana 312 (Multi Tumor-Associated Antigen T Cells) in Adults With AML/MDS After HSCT

NCT04679194

This is a Phase 1, open-label, non-randomized, single and multiple dose escalation study designed to evaluate the safety and preliminary efficacy of administering Mana 312 to subjects with AML/MDS after allogeneic HSCT.

Conditions: AML/MDS

Effects of Mitigation Treatments on Bruising of CCH-aaes Treatment of Buttock Cellulite

NCT04677712

QWO™ (CCH-aaes) is indicated for the treatment of moderate to severe cellulite in the buttocks of adult women. QWO™ (CCH-aaes)-related post-injection bruising was the most common adverse reaction; generally, resolving within 21 days. Since bruising may be bothersome to patients, this study will investigate treatments that may mitigate bruising after QWO™ (CCH-aaes) treatment of cellulite in the buttocks.

Conditions: Edematous Fibrosclerotic Panniculopathy (EFP), Cellulite

Validation of Patient Reported Outcome Measures in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex

NCT04677543

The primary objective of this study is to generate evidence demonstrating the domain specification via modern psychometric methods, reliability, validity, and responsiveness of Quality of Life - Bronchiectasis (QoL-B) and Patient-Reported Outcome Measurement Information System - Fatigue-Short Form (PROMIS F-SF 7a) in participants with newly diagnosed nontuberculous mycobacterial (NTM) lung infection caused by Myobaxterium avium Complex (MAC).

Conditions: Mycobacterium Infections, Nontuberculous

Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex

NCT04677569

The main objective of this study is to evaluate the efficacy of ALIS (amikacin liposome inhalation suspension) + Azithromycin + Ethambutol compared to the ELC (empty liposome control) + Azithromycin + Ethambutol on participant reported respiratory symptoms at Month 13.

Conditions: Mycobacterium Infections, Nontuberculous

The TRANQUILITY Trial: Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease

NCT04674358

The TRANQUILITY Trial: Multi-Center Randomized, Double-Masked, Parallel Design, Vehicle-Controlled Phase 2/3 Clinical Trial to Assess the Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects with Dry Eye Disease.

Conditions: Dry Eye, Dry Eye Syndromes
Phase: Phase 2/3